Showing results (71-80 of 156) with videos related to

Sort By:
Pageof 16
Expert Opinion on Investigational Drugs|April 30, 2021
Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemiaStefano Molica, David Allsup, Valentina Gianfelici, et al.
Hemasphere|September 9, 2022
What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice ExperimentLuca Laurenti, Gianluca Gaidano, Francesca Romana Mauro, et al.
European Journal of Haematology|December 14, 2005
Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progressionStefano Molica, Gaetano Vitelli, Rosanna Mirabelli, et al.
European Journal of Haematology|June 9, 2004
Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progressionStefano Molica, Gaetano Vitelli, Domenico Levato, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 29, 2021
Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: A Cost-Effectiveness AnalysisMarco Bellone, Lorenzo Pradelli, Stefano Molica, et al.
Leukemia & Lymphoma|July 15, 2006
Serum levels of syndecan-1 in B-cell chronic lymphocytic leukemia: correlation with the extent of angiogenesis and disease-progression risk in early diseaseStefano Molica, Gaetano Vitelli, Rosanna Mirabelli, et al.
Leukemia & Lymphoma|September 17, 2011
Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemiaGiuseppe Gritti, Gianluigi Reda, Francesco Maura, et al.
European Journal of Haematology|March 31, 2015
Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center modelStefano Molica, Diana Giannarelli, Rosanna Mirabelli, et al.
Experimental Hematology & Oncology|June 20, 2026
Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysisFederico Spataro, Vanessa Desantis, Giuseppe Dicuonzo, et al.
Haematologica|November 19, 2013
Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemiaFabio Efficace, Gianantonio Rosti, Neil Aaronson, et al.
Pageof 16